Next 10 |
home / stock / cprx / cprx articles
Jeffrey Del Carmen, Chief Commercial Officer at Catalyst Pharmaceuticals (NASDAQ:CPRX), executed a substantial insider sell on June 11, according t...
Revealing a significant insider sell on June 5, Molly Harper, Board Member at Catalyst Pharmaceuticals (NASDAQ:CPRX), as per the latest SEC filing....
Richard J Daly, President and CEO at Catalyst Pharmaceuticals (NASDAQ:CPRX), executed a substantial insider sell on June 5, according to an SEC fil...
CORAL GABLES, Fla., May 01, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a ...
CORAL GABLES, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (NASDAQ:CPRX), a commercial-stage, pa...
CORAL GABLES, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (NASDAQ:CPRX), a commercial-stage bio...
CORAL GABLES, Fla., March 05, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), ...
As of Feb. 29, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in t...
Achieved Record 2023 Total Revenues of $398.2 Million, an 85.9% Increase Compared to 2022 Achieved Record Fourth Quarter 2023 Total Revenu...
News, Short Squeeze, Breakout and More Instantly...
Catalyst Pharmaceuticals Inc. Company Name:
CPRX Stock Symbol:
NASDAQ Market:
Catalyst Pharmaceuticals Inc. Website:
2024-06-20 17:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-03 11:30:04 ET H.C. Wainwright analyst issues UNDERPERFORM recommendation for CPRX on June 3, 2024 09:00AM ET. The previous analyst recommendation was Underperform. CPRX was trading at $16.38 at issue of the analyst recommendation. The overall analyst consensus :...
2024-06-03 10:15:02 ET Oppenheimer analyst issues BUY recommendation for CPRX on June 3, 2024 09:00AM ET. The previous analyst recommendation was Buy. CPRX was trading at $16.38 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current anal...